Healthcare Industry News: Oncology information system
News Release - September 16, 2008
Accuray Incorporated and IMPAC Medical Systems to Link CyberKnife(R) Robotic Radiosurgery System with MOSAIQ(R) EMRPartnership underscores widespread adoption of the CyberKnife System and IMPAC's commitment to vendor independent connectivity
SUNNYVALE, Calif., Sept. 16 (HSMN NewsFeed) -- Accuray Incorporated (Nasdaq: ARAY ) and IMPAC Medical Systems, Inc. announced today that they will collaborate to develop inter-operability between the CyberKnife® Robotic Radiosurgery System and the MOSAIQ® Oncology information system. Using DICOM standard interface protocols, both treatment plan and delivery information from the CyberKnife System will automatically feed directly into the IMPAC electronic medical record.
Centralization of patient oncology data into a single, easily-accessible location is essential for state-of-the-art cancer care. With this capability, clinicians will have all necessary information readily available to make timely and informed medical decisions.
The CyberKnife System produces unique treatment records that are a vital element to the comprehensive patient chart. MOSAIQ's electronic data exchange automatically coordinates with the CyberKnife System, eliminating the need for manual data entry. Additionally, this capability further diminishes the need for paper charts ultimately providing clinicians with a single electronic source for accurate and up-to-date information.
"We were pleased to partner with IMPAC on this project. The majority of our CyberKnife customers utilize IMPAC's Oncology information system to manage their departments and patient records," said Euan S. Thomson, Ph.D., president and CEO of Accuray Incorporated. "This collaboration provides considerable value to our mutual customers, not only saving them time and effort, but also ensuring high-quality care."
"Since 1990, IMPAC has remained committed to vendor independent connectivity, enabling cancer centers to integrate data from various treatment delivery systems regardless of manufacturer," said Jay Hoey, president and CEO of IMPAC Medical Systems. "This solution represents our continued dedication to the open-systems initiatives as outlined by IHE-RO."
About IMPAC Medical Systems, Inc.
IMPAC Medical Systems, Inc. provides healthcare IT solutions that streamline clinical and business operations across the spectrum of cancer care. IMPAC's open integration to multiple healthcare data and imaging systems offers oncology-specific patient charting and practice management, as well as best-of-breed systems for anatomic pathology, clinical laboratory and cancer registry. With products that range from diagnosis and treatment through long- term follow-up, IMPAC provides a comprehensive oncology management solution that helps improve overall communication, process efficiency, and quality patient care.
Accuray Incorporated (Nasdaq: ARAY ), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently more than 140 Systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the year ended June 30, 2008 as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Unveils VOLO(TM) Ultra, the Latest Innovation for the Radixact(R) System, at ASTRO 2021
C-RAD and Accuray Sign Agreement to Enhance Radixact(R) System Breast Cancer Treatment Capabilities
French Hospital Network Unicancer Acquires Multiple Accuray Radixact(R) Systems with the ClearRT(TM) Helical Fan-Beam kVCT Imaging and Synchrony(R) Technologies